SEC Company Response from AETHLON MEDICAL INC (AEMD) (CIK 0000882291) (AEMD) — Jul 31, 2015
AETHLON MEDICAL INC (AEMD) (CIK 0000882291)
Date: July 31, 2015 · CIK: 0000882291 · Accession: 0001019687-15-002926
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-205832
Letter
VIA EDGAR Division of Corporation Finance Attention: Ms. Amanda Ravitz, Assistant Director Re: Aethlon Medical, Inc. Registration Statement on Form S-1 File No. 333-205832 REQUEST FOR ACCELERATION OF EFFECTIVENESS
Dear Ms. Ravitz and Ms. Percival:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aethlon Medical, Inc. (the “Registrant”) hereby respectfully requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-205832) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern Standard Time on August 4, 2015, or as soon as practicable thereafter.
The Registrant hereby authorizes Jennifer A. Post, of Raines Feldman LLP, to orally modify or withdraw this request for acceleration.
The Registrant hereby acknowledges that:
(i) should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(ii) the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
(iii) the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
We respectfully request that we be notified of such effectiveness by a telephone call to Ms. Post at 310.440.4100.
Very truly yours,
AETHLON MEDICAL, INC.
Show Raw Text
CORRESP
1
filename1.htm
9635 Granite Ridge Drive
Suite 100
San Diego, CA 92123
Phone 858-459-7800
July 31, 2015
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Attention:
Ms. Amanda Ravitz, Assistant Director
Ms. Heather Percival
Re:
Aethlon Medical, Inc.
Registration Statement on Form S-1
File No. 333-205832
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Dear Ms. Ravitz and Ms. Percival:
Pursuant to Rule 461 promulgated under the Securities
Act of 1933, as amended, Aethlon Medical, Inc. (the “Registrant”) hereby respectfully requests acceleration of the
effective date of its Registration Statement on Form S-1 (File No. 333-205832) (the “Registration Statement”), so that
it may become effective at 4:00 p.m. Eastern Standard Time on August 4, 2015, or as soon as practicable thereafter.
The Registrant hereby authorizes Jennifer A.
Post, of Raines Feldman LLP, to orally modify or withdraw this request for acceleration.
The Registrant hereby acknowledges that:
(i)
should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”),
acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from
taking any action with respect to the Registration Statement;
(ii)
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective,
does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration
Statement; and
(iii)
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the
Commission or any person under the federal securities laws of the United States.
We respectfully request that we be notified
of such effectiveness by a telephone call to Ms. Post at 310.440.4100.
Very truly yours,
AETHLON MEDICAL, INC.
/s/ James B. Frakes
James B. Frakes
Chief Financial Officer
cc: Jennifer A. Post, Raines
Feldman LLP